Apyx Medical Q1 revenue beats estimates, outlook raised

Apyx Medical

07/05/2026 12:08

Overview

US surgical aesthetics firm's Q1 revenue rose 32% yr/yr, beating analyst expectations

Q1 adjusted EBITDA loss narrowed and beat analyst expectations

Company raised full-year 2026 revenue guidance on strong Surgical Aesthetics and international sales

Outlook

Apyx Medical raises 2026 total revenue guidance to $59.0 mln-$60.0 mln, up from $57.5 mln-$58.5 mln

Company expects 2026 Surgical Aesthetics revenue of $54.0 mln-$55.0 mln, up from $53.0 mln-$54.0 mln

Apyx Medical expects OEM revenue of about $5.0 mln in 2026, up from $4.5 mln prior guidance

Result Drivers

SURGICAL AESTHETICS GROWTH - Revenue growth driven by increased adoption of AYON in the U.S., higher international sales of Renuvion generators, and greater volume of single-use handpieces

INTERNATIONAL SALES - International sales exceeded expectations, helped by Apyx One Console and handpiece sales in South Korea after regulatory approval

GROSS MARGIN IMPROVEMENT - Higher gross margin attributed to greater share of Surgical Aesthetics in sales mix and product mix within OEM segment

Company press release: ID:nGNX3t3Dzg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$12.49 mln
$10.87 mln (4 Analysts)
Q1 EPS
-$0.05
Q1 Net Income
-$2.14 mln
Q1 Adjusted EBITDA
Beat
-$326,000
-$3.31 mln (3 Analysts)
Q1 Gross Margin
63.50%
Q1 Income From Operations
-$911,000
Q1 Pretax Profit
-$2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Apyx Medical Inc is $6.00, about 105.5% above its May 6 closing price of $2.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)